Dexcom Inc (DXCM) concluded trading on Thursday at a closing price of $78.93, with 3.05 million shares of worth about $240.45 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -30.65% during that period and on December 12, 2024 the price saw a loss of about -1.91%. Currently the company’s common shares owned by public are about 390.60M shares, out of which, 385.55M shares are available for trading.
Stock saw a price change of 0.01% in past 5 days and over the past one month there was a price change of 6.17%. Year-to-date (YTD), DXCM shares are showing a performance of -36.39% which decreased to -33.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $62.34 but also hit the highest price of $142.00 during that period. The average intraday trading volume for Dexcom Inc shares is 4.18 million. The stock is currently trading 1.77% above its 20-day simple moving average (SMA20), while that difference is up 7.64% for SMA50 and it goes to -20.23% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Dexcom Inc (NASDAQ: DXCM) currently have 390.60M outstanding shares and institutions hold larger chunk of about 93.19% of that.
The stock has a current market capitalization of $30.83B and its 3Y-monthly beta is at 1.13. PE ratio of stock for trailing 12 months is 47.31, while it has posted earnings per share of $1.67 in the same period. Its PEG reads 2.20 and has Quick Ratio of 2.12 while making debt-to-equity ratio of 1.31. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DXCM, volatility over the week remained 2.97% while standing at 3.34% over the month.
Stock’s fiscal year EPS is expected to rise by 12.23% while it is estimated to increase by 19.53% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on July 26, 2024 offering a Neutral rating for the stock and assigned a target price range of between $161 and $80 to it. Coverage by JP Morgan stated Dexcom Inc (DXCM) stock as a Neutral in their note to investors on July 26, 2024, suggesting a price target of $75 for the stock. On May 30, 2024, Redburn Atlantic Initiated their recommendations, while on March 12, 2024, RBC Capital Mkts Initiated their ratings for the stock with a price target of $165. Stock get an Equal-weight rating from Morgan Stanley on May 30, 2023.
